Biogen Inc. (NASDAQ: BIIB) experienced a notable 2.26% increase in stock price, closing at $193.76, following a mixed readout from its Phase 2 CELIA trial of diranersen, an experimental Alzheimer’s treatment. While the drug missed its primary endpoint, it showed significant reductions in tau pathology and signs of slower cognitive decline, which has kept investor interest alive in Biogen’s long-term Alzheimer’s strategy.
The market reacted sharply to the trial results, causing a more than 10% drop in Biogen’s stock shortly after the announcement. However, analysts remain cautiously optimistic, with a consensus price target of $215.62, suggesting a potential upside of about 14%. The ongoing success of Biogen’s approved Alzheimer’s treatment, Leqembi, which saw a 74% year-over-year sales increase, further supports the company’s revenue stability.
For market professionals, the key takeaway is that despite the recent volatility, Biogen’s stock may present a buying opportunity, particularly if it holds above the 50-day moving average around $185, signaling a potential continuation of its upward trend ahead of critical upcoming FDA decisions.
Source: marketbeat.com